CIM
MDGL icon

Contravisory Investment Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Contravisory Investment Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.3K Hold
23
– – ﹤0.01% 343
2026
Q1 		$12K Hold
23
– – ﹤0.01% 335
2025
Q4 		$13.4K Buy
+23
New +$11.7K ﹤0.01% 322

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Contravisory Investment Management's MDGL Position: Q2 2026 in Review

Contravisory Investment Management held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 23 shares worth $12.3K. The position accounts for ﹤0.01% of the portfolio, ranked #343.

Contravisory Investment Management first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. The position peaked at $13.4K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Contravisory Investment Management held 23 shares of Madrigal Pharmaceuticals worth $12.3K as of Q2 2026.
  • Contravisory Investment Management left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Contravisory Investment Management's portfolio in Q2 2026, its #343 holding.
  • Contravisory Investment Management first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Contravisory Investment Management's Madrigal Pharmaceuticals position peaked at $13.4K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Contravisory Investment Management's 13F filing for Q2 2026, filed 9 Jul 2026.